Background: Robust approaches to quantify tumor heterogeneity are needed to provide early decision support for precise individualized therapy. Purpose: To conduct a technical exploration of longitudinal changes in tumor heterogeneity patterns on dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI), diffusion-weighted imaging (DWI) and FDG positron emission tomography / computed tomography (PET/CT), and their association to radiation therapy (RT) response in cervical cancer. Study Type: Prospective observational study with longitudinal MRI and PET/CT pre-RT, early-RT (2 weeks), and mid-RT (5 weeks). Population: Twenty-one FIGO IB 2 -IVA cervical cancer patients receiving definitive external beam RT and brachytherapy. Field Strength/Sequence: 1.5T, precontrast axial T 1 -weighted, axial and sagittal T 2 -weighted, sagittal DWI (multi-b values), sagittal DCE MRI (<10 sec temporal resolution), postcontrast axial T 1 -weighted. Assessment: Response assessment 1 month after completion of treatment by a board-certified radiation oncologist from manually delineated tumor volume changes. Statistical Tests: Intensity histogram (IH) quantiles (DCE SI 10% and DWI ADC 10% , FDG-PET SUV max ) and distribution moments (mean, variance, skewness, kurtosis) were extracted. Differences in IH features between timepoints and modalities were evaluated by Skillings-Mack tests with Holm's correction. Area under receiver-operating characteristic curve (AUC) and Mann-Whitney testing was performed to discriminate treatment response using IH features. Results: Tumor IH means and quantiles varied significantly during RT (SUV mean : #28-47%, SUV max : #30-59%, SI mean : "8-30%, SI 10% : "8-19%, ADC mean : "16%, P < 0.02 for each). Among IH heterogeneity features, FDG-PET SUV CoV (#16-30%, P 5 0.011) and DW-MRI ADC skewness decreased (P 5 0.001). FDG-PET SUV CoV was higher than DCE-MRI SI CoV and DW-MRI ADC CoV at baseline (P < 0.001) and 2 weeks (P 5 0.010). FDG-PET SUV kurtosis was lower than DCE-MRI SI kurtosis and DW-MRI ADC kurtosis at baseline (P 5 0.001). Some IH features appeared to associate with favorable tumor response, including large early RT changes in DW-MRI ADC skewness (AUC 5 0.86).
Data Conclusion: Preliminary findings show tumor heterogeneity was variable between patients, modalities, and timepoints. Radiomic assessment of changing tumor heterogeneity has the potential to personalize treatment and power outcome prediction. A lthough heterogeneity of tumor cells 1 and their microenvironment 2-4 greatly impact patient-specific response to cancer therapy, including cervical cancer therapy, 5, 6 strategies for objectively quantifying and associating tumor heterogeneity to outcome have yet to be standardized and validated for clinical implementation. Evaluation of regional tumor microscopic heterogeneity can be achieved by invasive biopsy, but cannot evaluate the entire tumor bed, and is prone to sampling error. Furthermore, it is difficult to perform sequential biopsy of specific tumor regions and assess temporal changes due to morphologic changes of the tumor as it shrinks during treatment. 7 A robust and noninvasive approach to quantify tumor heterogeneity, prior to or early during treatment, may have a profound impact on the management of individual cancer patients by providing early prediction of treatment outcome and the opportunity to tailor therapy as part of the precision medicine paradigm. 8 Radiomics is an expanding field of clinical research that extracts high dimensional sets of imaging features for association with clinical diagnosis, prognosis, and therapeutic interventions. Unlike tissue biomarkers, which invasively sample a small tumor region at the micron spatial scale, radiomic biomarkers noninvasively interrogate the entire tumor at the millimeter scale over multiple timepoints. Radiomics features of tumor heterogeneity show promise as predictive correlates of clinical outcomes in a variety of cancer patients 9 and have also been linked to oncogenic expression. 10 The majority of published investigations on tumor radiomics have focused on a single imaging modality, predominantly computed tomography (CT), magnetic resonance imaging and to a lesser extent positron emission tomography (PET). In cervical cancer patients, changes in FDG PET standardized uptake value (SUV) metrics posttherapy predict recurrent disease and clinical outcome, 11, 12 but these changes after treatment completion cannot be utilized to directly adapt or alter the initial definitive treatment course in order to improve outcome. Pretreatment FDG PET uptake gradients are also associated with treatment response and recurrence risk, but correlation of these uptake gradients with simpler volumetric imaging measures suggests limited complementary information. 13 High-dimensional sets of textural features on FDG PET change dynamically with therapy. 14 Further validation of their clinical utility for patient treatment outcome prediction will depend on judicious feature selection. 15 Diffusion-weighted (DW) MRI has proven useful in the management of cervical cancer, 16 with features of apparent diffusion coefficient (ADC) that detect early signs of treatment response. 17 It remains unclear whether combinations of MRI and PET metrics of tumor heterogeneity can demonstrate improved prediction of treatment response and clinical outcome, 18 particularly when evaluating temporal changes of multimodal imaging features across treatment timepoints. The purpose of this study was to conduct a technical exploration of longitudinal changes in tumor heterogeneity patterns on DCE MRI, DWI, and FDG PET/CT, as well as preliminary association with response to radiation therapy (RT) therapy in cervical cancer patients. This extends prior work on DCE MRI features of at-risk tumor regions that demonstrated high prognostic value.
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Materials and Methods
Patient and Treatment Characteristics
Twenty-one patients with cervical cancer of variable stage (FIGO IB 2 -IVA) were prospectively enrolled into an observational study (NCT01992861) following approval by the Institutional Review Board at the University of Washington and after obtaining each patient's informed consent. Three serial MRI and three serial PET examinations were performed before and during treatment. Pretreatment clinical evaluations included routine initial clinical workup following FIGO guidelines. 21 Patients were treated with standard external beam RT, concurrent weekly cisplatin-based chemotherapy, and standard-of-care brachytherapy. External beam RT dose prescriptions ranged from 45.0-50.4 Gy in conventional 1.8 Gy per fraction, including whole pelvis and cone down radiation fields. High dose rate 192 Ir brachytherapy ranged from 30.0-39.6
Gy biologically equivalent dose in 2 Gy according to the linearquadratic model of cell survival for cervical cancer (a/b 5 10).
DCE MRI, DW MRI, and FDG PET/CT Acquisition
Patients underwent serial MRI and PET examinations at three timepoints: prior to external beam RT, early during external beam RT (at 20-25 Gy of pelvic RT), and midway during RT (at 40-50 Gy). MRI examinations were performed on 1.5T scanners (SIGNA series, GE Healthcare, Waukesha, WI) and included precontrast axial T 1 -weighted, axial and sagittal T 2 -weighted, and sagittal DWI sequences, followed by sagittal DCE MRI and postcontrast axial T 1 -weighted sequences. Further details of the DCE MRI imaging protocol can be found in a prior study. 22 The images used for quantitative analysis in the research study were the matched sagittal T 2 -weighted, DWI, and DCE MRI sequences, described in more detail below. Precontrast T 2 -weighted imaging was performed using a 2D fast spin echo sequence with TR 300-5000 msec, echo time (TE) 100-120 FDG PET/CT examinations (Discovery STE, GE Healthcare) were conducted at timepoints that coincided with MRI examinations prior to and during radiation therapy. The exam consisted of a helical CT for attenuation correction, reconstructed to 2-mm slice thickness for improved MR-CT registration, followed by a whole-body static PET acquisition spanning 6-7 axial fields of view and 5 minutes per couch position. PET imaging commenced 60 minutes postweight-based FDG injection (nominal) with the most caudal axial FOV so as to minimize FDG bladder fillinginduced artifact in the pelvis. Images were reconstructed using ordered subset expectation maximization (OSEM) and a postreconstruction 3D Gaussian filter was applied.
Intensity Histogram Feature Extraction
DCE MRI signal intensity (SI) ratio, DW MRI ADC, and FDG PET SUV images generated on the respective scanners were coregistered to the reference sagittal T 2 -weighted MR image at each timepoint using a rigid normalized mutual information algorithm (MIM 6.5, MIM Software, Cleveland, OH) applied between MR-MR and MR-CT (PET). Image processing of DCE MRI to generate SI ratio maps has been described previously. 22 In brief, the first-pass DCE plateau phase was identified on the time-intensity curve. The plateau phase and precontrast phase of the DCE time series were fused and adjustments in alignment were applied to account for interframe tumor motion. From this fusion, the SI ratio of the plateau phase and precontrast phase was computed at every voxel that produced the final SI ratio images. Tumor and uterus volumes were delineated on the reference MRI (sagittal T 2 -weighted), with the latter structure assisting in final anatomic alignment of all images due to bladder and rectal filling-induced changes in uterus position. The reference tumor contour at each timepoint was rigidly copied to the DCE MR SI ratio, DWI ADC, and FDG PET image sets and converted to their respective native digital grids. Voxels on DWI ADC maps that suffered from significant distortion artifacts at air-tissue interfaces were excluded from the analysis through automatic thresholding, while voxels on FDG PET impacted by spill-in of bladder signal were similarly removed. Voxel value distributions of each image modality were extracted from the tumor contour on the native grid without digital resampling, which preserved covariance in image voxel neighborhoods at the cost of contour boundary variability. The resultant process introduced a small contour transformation rather than a large image value transformation. Due to these variations in contour boundaries between imaging modalities, particularly in small residual tumors at the 5-week mid-RT timepoint, we focused our investigation on intensity histogram (IH) features. Other radiomic features of image texture can be sensitive to region of interest (ROI) size and ROI boundary shape. 23 The following set of IH features were extracted from the tumor ROI at each timepoint for each image modality (DCE SI ratio, DWI ADC, FDG PET SUV): 1) mean: 1 st moment of intensity distribution;
2) coefficient of variation: standard deviation divided by the mean, representing normalized 2 nd moment of intensity distribution;
3) skewness: normalized 3 rd moment of intensity distribution; 4) kurtosis: normalized 4 th moment of intensity distribution; 5) quantiles: DCE SI ratio 10 th percentile, DWI ADC 10 th percentile, FDG PET SUV maximum of the respective intensity distributions.
The moments of the intensity distribution describe the shape of the IH as statistical measures of heterogeneity. The quantiles represent the most commonly reported values associated with specific tumor voxels / regions (low perfusion, low diffusion, high glucose metabolism) that are presumed to be more resistant to therapy.
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Statistical Analysis
For each image modality, differences in IH feature distributions between timepoints (pretreatment, 2-week early-treatment, and 5-week mid-treatment) were evaluated using the nonparametric Skillings-Mack test. 25 This statistical test is analogous to the Wilcoxon signed-rank test for paired data but allows for three or more groups to be compared. At each timepoint, differences in IH feature distributions between modalities (FDG PET, DCE MRI, DW MRI) were also evaluated using the Skillings-Mack test. Two-tailed P values were adjusted for multiple comparisons using Holm's method, which is a more powerful alternative to the Bonferroni correction. 26 The multiple comparison adjustment was applied separately to the group of tests comparing timepoints and the group of tests comparing modalities. An exploratory analysis of individual IH features and changes in features during therapy were compared between patients with and without tumor response assessed at 1 month after the completion of brachytherapy, using the Mann-Whitney test. Tumor response was defined as <10% residual volume from baseline. The area under the receiver operating characteristic (ROC) curve (AUC) was used to summarize the strength of association between each individual IH feature and response. Multivariate regression analysis was not performed due to the small sample size. As this part of the analysis was exploratory and hypothesisgenerating in nature, the corresponding P-values were not adjusted for multiple comparisons. All statistical analyses were conducted in OriginLab Pro 9.1 (Northampton, MA) or the R statistical computing language (v. 3.1.1; R Foundation for Statistical Computing, Vienna, Austria).
Results
Images and image IHs are shown for a representative patient in Figures 1 and 2 , respectively, at each timepoint (pretreatment, 2-week early-treatment, 5-week mid-treatment) and for each modality (FDG PET, DCE MRI, DW MRI). Figure 1 shows the time-dependent tumor (magenta contour) decrease in SUV on FDG PET (top row), increase in DCE signal enhancement on MRI (middle row), and variable ADC on MRI (bottom row). Figure 2 displays the corresponding IHs of the images of the same patient, whose characteristic tumor heterogeneity included small increases in FDG PET SUV skewness (right-skewed) along with large decreases in DCE MR skewness and DW MR ADC skewness (left-skewed) with therapy. Large tumor volume regression was observed on the 5-week mid-treatment images and histograms.
Characteristic time-dependent trends were observed for the heterogeneity properties of DCE, ADC, and FDG PET SUV during treatment. Mean and quantile IH features evolved significantly during RT, and the changes during therapy were not concordant among the functional imaging parameters. SUV mean and SUV max both decreased during treatment by 28-47% and by 30-59%, respectively (adjusted P < 0.001), relative to baseline values. Conversely, the DCE parameters SI mean and SI 10% increased by 8-30% and 8-19%, respectively (adjusted P < 0.015), and ADC mean increased by 16% (adjusted P < 0.001), relative to baseline values. Among the IH features of heterogeneity, the greatest changes were observed in FDG PET SUV and ADC. The SUV coefficient of variation decreased intratreatment by 16-30% (adjusted P 5 0.011), and ADC skewness decreased by 0.62-0.95 (adjusted P 5 0.001). SUV kurtosis showed only small longitudinal changes during treatment, whereas DCE (adjusted P 5 0.21) and ADC kurtosis (adjusted P 5 0.075) numerically decreased from the pretherapy to the 2-week mid-treatment imaging, although these trends did not reach statistical significance. Figure 3 summarizes the timedependent changes of MRI and PET image features during radiation therapy for the patient cohort. Figure 4 illustrates the imaging modality-dependent differences in IH features at each timepoint prior to and during treatment. The coefficient of variation of FDG PET SUV was significantly higher than the coefficient of variation of DCE MRI SI or DW MRI ADC prior to treatment (adjusted P < 0.001) and at 2 weeks during treatment (adjusted P 5 0.01). The kurtosis of FDG PET SUV was lower prior to treatment than kurtosis of DCE MRI SI and DW MRI ADC (adjusted P 5 0.001).
A hypothesis-generating analysis was conducted, correlating 1-month posttreatment response with individual IH features (Table 1) . Out of the 21 subjects, one without sufficient follow-up to determine response was excluded from this analysis. Six features were found to be significantly associated with response (P < 0.05 without adjustment for multiple comparisons), with greater decreases in DW-MRI ADC skewness (becoming more left-skewed) between the baseline and 2-week FIGURE 1: MRI-PET fusion, DCE MR plateau (postcontrast), and DW MR ADC images for a representative patient at three different timepoints: prior to radiation therapy, early during RT (2 weeks), and midway during RT (5 weeks). Gross tumor was delineated at each timepoint (magenta contour), from which voxel distribution histogram features were extracted. Tumor voxels suffering from bladder artifact on FDG PET or distortion artifacts on DW MRI were excluded by threshold from calculation of SUV and ADC histogram features, respectively. Note the variable heterogeneity in image intensity between modalities (FDG PET, DCE MRI, DW MRI) and variable changes during therapy.
scan having the strongest observed association with favorable treatment response (AUC 5 0.86).
Discussion
Although the biological heterogeneity of cervical cancer plays an important role in patient-specific tumor sensitivity to therapy, 5 strategies for objectively quantifying and associating tumor heterogeneity to outcome have yet to be standardized and validated for clinical implementation. Functional and molecular imaging voxels represent millimeter-scale resolution, and thereby are incapable of resolving the microscopic heterogeneity observable on tumor biopsy specimens. On the other hand, invasive biopsy-based evaluation does not encompass the entire tumor bed nor can it perform reliable longitudinal assessment of tumor heterogeneity during therapy. 7, 27 Invasive biopsy assessment of tumor heterogeneity is also less feasible for deeply seated tumors and those in close proximity to vital structures, such as major nerves and blood vessels.
Despite its limitations, image voxel-derived heterogeneity as part of radiomics analysis is closely related to biologic heterogeneity when using PET, 28, 29 CT, 10, 30 or MRI. 31, 32 Such radiomic heterogeneity provides a noninvasive technique to obtain essential information of "macro-heterogeneity" over the entire tumor burden of disease, and can quantify temporal changes in tumor heterogeneity during cytotoxic cancer therapy. Macroscopic tumor heterogeneity derived from image voxel intensity distributions would also facilitate clinical translation of targeted tumor treatment, such as surgical resection or radiation therapy that carry the same inherent millimeter level of delivery precision. Radiomic biomarkers of tumor heterogeneity may eventually complement existing genomic and proteomic biomarkers to form a unique patient profile that informs personalized care strategies. This exploratory technical investigation established a generalized framework for extracting multimodal imaging features of tumor heterogeneity, and demonstrated two key FIGURE 2: Intensity histograms of FDG-PET SUV, DCE-MRI SI ratio, and DW-MRI ADC at timepoints prior to, 2 weeks during, and 5 weeks during external beam radiation therapy for the same patient as in Figure 1 , from which quantitative features of heterogeneity can be extracted. Note the variable histogram shapes and distributions between modalities and across timepoints. This patient is characterized by increasing FDG-PET SUV skewness, decreasing DCE-MRI SI ratio skewness, and decreasing DW-MRI ADC skewness with therapy.
observations: tumor heterogeneity varies between image modality for the same patient, and tumor heterogeneity varies between timepoints during cytotoxic therapy for the same image modality. Statistical differences in certain heterogeneity metrics between PET and MRI techniques suggest that they may provide complementary information for response assessment and outcome prediction of cervical cancer patients. The following longitudinal changes in image features of tumor heterogeneity across the patient cohort were observed between baseline and midtherapy timepoints: FDG PET SUV decrease, DCE MRI SI (plateau enhancement ratio) increase, DW MRI ADC increase, FDG PET SUV coefficient of variation decrease, and DW MRI ADC skewness decrease. Our observation of a DW MRI ADC increase during treatment is consistent with previous reports that show a general trend of improved diffusion in cervical , and range (whisker) across the patient cohort are shown for each imaging modality. Distributions of radiomic features were compared between imaging timepoints for each modality using the Skillings-Mack nonparametric test. P values were adjusted for multiple comparisons: *P < 0.05, **P < 0.01, ***P < 0.001. , and range (whisker) across the patient cohort are shown for each timepoint. Distributions of radiomic features at the same timepoint were compared between modalities using the Skillings-Mack nonparametric test. P values were adjusted for multiple comparisons: *P < 0.05, **P < 0.01, ***P < 0.001.
cancer with radiation 17 that relate to increased water motility, increased microvessel density, 33 and reduced tumor cellularity during treatment. Similarly, the observed DCE MRI SI increase suggests improvements in blood perfusion with therapy. 19, 20, 22, [34] [35] [36] [37] Lastly, the reduction in mean and maximum FDG PET SUV during therapy is in keeping with observations of declining tumor glycolytic metabolism 24 that relate to glucose transporter expression. 28 This represents the first study to report on DCE MRI, DWI, and FDG PET imaging features of cervical cancer heterogeneity in the same patient cohort and their changes during therapy. We found that FDG-PET IH feature changes during therapy are different than analogous DCE-MRI and DW-MRI IH feature changes. We did not observe a correlation of pretherapy FDG-PET SUV with DW-MRI ADC, as previously reported, 38 nor were the time-dependent changes in parameters concordant between PET and MRI. Decreases in FDG-PET SUV coefficient of variation suggest that radiation therapy may lower intratumor metabolic heterogeneity. Decreases in DW-MRI ADC skewness are characteristic of large tumor region shifts to higher levels of diffusion coupled with smaller tumor regions of persistently low diffusion. Beyond population trends, high variability in IH features between individual patients was observed through large interquartile and overall ranges. Such intertumor variation and unique temporal evolution of imaging heterogeneity may provide critical insight into individual patient response to therapy. A strength of the proposed framework is its design around IH distribution feature changes instead of image voxel changes during therapy, making it substantially less sensitive to stochastic uncertainties in image formation and therefore well suited to multimodality patient data. It has been recently reported that these image formation uncertainties can have a detrimental effect on quantitation of certain radiomic features 23 and necessitate comprehensive standardization. 39 Methods to analyze multimodal image data on a grid of common voxel size can compromise quantitative accuracy of tumor radiomic heterogeneity, since MRI reconstruction grids consist of high in-plane resolution but coarse slice thickness in most 2D acquisitions, whereas PET reconstructions grids consist of nearly isotropic coarse resolution from 3D acquisitions. The IH feature extraction in this study was performed on the native digital reconstruction grid of each MRI and PET image to preserve the voxel intensity distributions. Furthermore, longitudinal response assessment of IH features does not require deformable image registration if independent contours are generated at each timepoint. This is an important consideration in disease sites with substantial morphological tumor changes in response to therapy, highlighted here when applied to cervical cancer. Lastly, distortion artifacts that present on DW-MRI ADC maps late in cervical cancer therapy due to variable airtissue rectal interfaces challenge the accuracy of voxel-based response assessment and even textural feature response assessment, but are mitigated by IH-based response assessment through careful exclusion of distorted tumor voxels.
As part of a hypothesis-generating subanalysis, we identified several candidate IH features that may correlate with 1-month posttreatment response. In particular, greater decreases in DW-MRI ADC skewness at 2 weeks, relative to baseline, appeared to be associated with an increased likelihood of tumor response and had the largest estimated AUC among the IH features. This supports the argument that left-skewed distribution shifts to higher tumor diffusion result in favorable treatment response, which may be biologically tied to a higher proportion of tumor volume with declining cellularity as a result of sensitivity to radiation. However, this subanalysis is exploratory, without adjustment for the number of comparisons, and the associated findings need to be replicated in a larger study before they can be utilized.
The general framework to extract multimodal tumor heterogeneity features can identify candidate imaging biomarkers for application to outcome prediction during and following therapeutic intervention. Such predictions can inform on selection, dosing, and sequencing of novel combination therapies guided by functional imaging. This will promote personalized therapeutic approaches in patients who are adapted to radiomic profiles of tumor heterogeneity. The tools developed under this framework can be integrated into clinical workflows through standardized reporting of radiomic features, analogous to genomic and proteomic features. Causal relationships between these features can be characterized on a patient-specific basis, 40 leading to future omics analyses of imaging and tissue biomarkers of tumor heterogeneity. The investigation has several limitations. The sample size is small and we do not report long-term follow-up for outcome prediction. A larger sample size would provide the necessary statistical power to examine higher-dimensional sets of radiomics features beyond image intensity, including those derived from image texture and shape. A larger sample would also power the construction and validation of a multivariate model for clinical outcome prediction. Given these limitations, our preliminary study was focused on characterization of select image features and identifying candidate imaging biomarkers of therapeutic response. Other limitations include anatomical variations between imaging studies, during the same imaging study (eg, between different pulse sequences, frames of the DCE time-series) or at different treatment timepoints. These were caused by differences in bladder filling, rectal distention, or imaging position. Strict protocol standardization, patient fasting instructions, image coregistration, and image IH feature extraction methodology minimized the impact of this variability. Despite the small sample size and other inherent limitations, we were able to detect substantial changes in IH features over time and differences between modalities while accounting for multiple comparisons. Further investigation of these candidate imaging biomarkers of tumor heterogeneity is warranted in a larger patient population to train and validate multivariate models for outcome prediction early during therapy.
An exploratory technical investigation of tumor radiomic heterogeneity analysis of multimodal DCE MRI, DW MRI, and FDG PET was developed to identify candidate imaging biomarkers of treatment response. Image IH features of tumor heterogeneity varied between patients, between modalities, and between timepoints during radiation therapy. The characteristic heterogeneity patterns shown with different imaging features and their temporal changes at different treatment timepoints offer great potential for incorporation into precision radiation oncology. These preliminary results will require further confirmation within a larger patient population and validation of tumor radiomic heterogeneity for clinical outcome prediction.
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